Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ascendis Pharma logo — Committed to making a meaningful difference for patients

Ascendis Pharma

Committed to making a meaningful difference for patients

Founded 2007 Denmark Denmark 1046 employees Post Ipo Debt Total: $1.42B Biotechnology, Health Care

General Information

Company Name Ascendis Pharma
Founded Year 2007
Location Denmark Denmark +1
Employees 1046
Industries Biotechnology, Health Care
Funding Stage Post Ipo Debt
Social

Get notified when Ascendis Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ascendis Pharma

Ascendis Pharma is a biopharmaceutical company committed to making a meaningful difference for patients. The company is guided by its core values of patients, science, and passion and is applying innovative TransCon technology to create new and potentially best-in-class therapies. Currently, Ascendis Pharma has three independent endocrinology rare disease product candidates in clinical development and is also advancing programs in Oncology and Ophthalmology. The company is headquartered in Copenhagen, Denmark with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey. Having been founded in 2006, Ascendis Pharma has seen significant investment, with the last investment of $150.00M Post-IPO Debt being made on 05 September 2023, with Royalty Pharma as the investors. The company operates within the Biotechnology and Health Care industries, positioning itself as an innovative leader in the field of biopharmaceuticals.

Taxonomy: Biopharmaceutical, Rare Diseases, Clinical Development, Oncology, Ophthalmology, TransCon Technology, Drug Development, Innovation, Endocrinology, Prodrug Technology, Globalization, New Chemical Entities, Patient-Centric, High-Value Pipeline, Unmet Medical Need

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• 1 •••• •••• 05 Sep 2023
Post-IPO Debt •••••• - 24 Mar 2022
Post-IPO Equity •••••• - 07 Jul 2020
Post-IPO Equity •••••• 1
Investor
01 Jan 2017
Series D •••••• 6
Investor Investor Investor Investor Investor Investor
01 Dec 2014

View All 6 Funding Rounds

Ascendis Pharma Alternatives & Competitors

Ascendis Pharma vs
VISEN Pharmaceuticals
VISEN Pharmaceuticals China

Achieve better treatment processes and outcomes by combining global expertise and strength in endocr...

Series B
42 employees
Biotechnology, Life Sciences
Compare Ascendis Pharma vs VISEN Pharmaceuticals
Ascendis Pharma vs
BioFilm Pharma
BioFilm Pharma France

The next generation of Antimicrobials will be Antibiofilms.

3 employees
Pharmaceutical
Ascendis Pharma vs
Prescribery
Prescribery United States

Solutions Beyond Telemedicine: Allowing pharmaceutical manufacturers compliant, consumer-direct medi...

18 employees
Health Care, Health and Wellness
Also compare with: Ascendis Pharma vs Sumitomo Pharma Oncology Sumitomo Pharma Oncology Ascendis Pharma vs Ascendis Health Ascendis Health Ascendis Pharma vs XSPRAY PHARMA AB (PUBL) XSPRAY PHARMA AB (PUBL)

FAQ About Ascendis Pharma

Committed to making a meaningful difference for patients
Ascendis Pharma was founded in 2007.
Ascendis Pharma is headquartered in Denmark.
Ascendis Pharma operates in the following industries: Biotechnology, Health Care.
Ascendis Pharma has approximately 1046 employees.
Ascendis Pharma has completed 6 funding rounds, raising a total of $1.42B. The latest funding stage is Post Ipo Debt.
Top alternatives and competitors to Ascendis Pharma include VISEN Pharmaceuticals, BioFilm Pharma, Prescribery, Deccan Transcon Leasing Limited, Sumitomo Pharma Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ascendis Pharma and VISEN Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ascendis Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes